Related references
Note: Only part of the references are listed.Benefit of tumor resection for recurrent glioblastoma
Johanna Quick et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
Generation and validation of a prognostic score to predict outcome after re-irradiation of recurrent glioma
Stephanie E. Combs et al.
ACTA ONCOLOGICA (2013)
Surgical outcomes in recurrent glioma Clinical article
Jason M. Hoover et al.
JOURNAL OF NEUROSURGERY (2013)
Standards of care for treatment of recurrent glioblastoma-are we there yet?
Michael Weller et al.
NEURO-ONCOLOGY (2013)
Glioblastoma survival in the United States before and during the temozolomide era
Derek R. Johnson et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Impact of extent of resection for recurrent glioblastoma on overall survival Clinical article
Orin Bloch et al.
JOURNAL OF NEUROSURGERY (2012)
Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion
Walter Stummer et al.
ACTA NEUROCHIRURGICA (2011)
Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy
David A. Reardon et al.
CANCER (2011)
Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study
John F. de Groot et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
An extent of resection threshold for newly diagnosed glioblastomas
Nader Sanai et al.
JOURNAL OF NEUROSURGERY (2011)
Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?
Jennifer L. Clarke et al.
NEURO-ONCOLOGY (2011)
Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme
R. Helseth et al.
ACTA NEUROLOGICA SCANDINAVICA (2010)
A Phase 2 Trial of Single-Agent Bevacizumab Given in an Every-3-Week Schedule for Patients With Recurrent High-Grade Gliomas
Jeffrey J. Raizer et al.
CANCER (2010)
Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma
Michael Brada et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Scale to Predict Survival After Surgery for Recurrent Glioblastoma Multiforme
John K. Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma
Wolfgang Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
James R. Perry et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Extended-schedule dose-dense temozolomide in refractory gliomas
A. Berrocal et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma
Doo-Sik Kong et al.
NEURO-ONCOLOGY (2010)
Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial
Benedikte Hasselbalch et al.
NEURO-ONCOLOGY (2010)
Two phase II trials of temozolomide with interferon-α2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme
M. D. Groves et al.
BRITISH JOURNAL OF CANCER (2009)
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
D. A. Reardon et al.
BRITISH JOURNAL OF CANCER (2009)
Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
Alba A. Brandes et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival
Mehul Patel et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma
Maria Grazia Fabrini et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival
Ashwatha Narayana et al.
JOURNAL OF NEUROSURGERY (2009)
EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME
et al.
NEUROSURGERY (2009)
Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience
Silvia Scoccianti et al.
ANTI-CANCER DRUGS (2008)
Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas
Casilda Balmaceda et al.
CANCER (2008)
Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme
David A. Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy
Ellen S. Mandl et al.
SURGICAL NEUROLOGY (2008)
Iatrogenic immunosuppression in patients with newly diagnosed high-grade gliomas
S. A. Grossman et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials
Kathryn A. Carson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: Long-term results in 172 patients treated in a single institution
SE Combs et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas
H Ohgaki et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2005)
Hypofractionated stereotactic re-irradiation:: Treatment option in recurrent malignant glioma -: art. no. 55
D Vordermark et al.
BMC CANCER (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy
GE Keles et al.
JOURNAL OF NEUROSURGERY (2004)
A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival
M Lacroix et al.
JOURNAL OF NEUROSURGERY (2001)
Experiences with reoperation on recurrent glioblastoma multiforme
M Pinsker et al.
ZENTRALBLATT FUR NEUROCHIRURGIE (2001)
Share Paper
